Ameritas Investment Company LLC Buys Shares of 1,179 IQVIA Holdings Inc. (NYSE:IQV)

Ameritas Investment Company LLC bought a new stake in IQVIA Holdings Inc. (NYSE:IQV) in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 1,179 shares of the medical research company’s stock, valued at approximately $228,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of IQV. Los Angeles Capital Management LLC lifted its stake in shares of IQVIA by 12.5% in the fourth quarter. Los Angeles Capital Management LLC now owns 66,567 shares of the medical research company’s stock worth $11,927,000 after buying an additional 7,380 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in shares of IQVIA in the fourth quarter worth $111,000. LPL Financial LLC lifted its stake in shares of IQVIA by 29.7% in the fourth quarter. LPL Financial LLC now owns 48,812 shares of the medical research company’s stock worth $8,746,000 after buying an additional 11,164 shares during the last quarter. Penserra Capital Management LLC lifted its stake in shares of IQVIA by 29.7% in the fourth quarter. Penserra Capital Management LLC now owns 397 shares of the medical research company’s stock worth $71,000 after buying an additional 91 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its stake in shares of IQVIA by 0.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 932,155 shares of the medical research company’s stock worth $167,015,000 after buying an additional 3,101 shares during the last quarter. Hedge funds and other institutional investors own 86.31% of the company’s stock.

IQV opened at $243.03 on Thursday. The stock has a 50-day moving average price of $242.00. The company has a current ratio of 1.15, a quick ratio of 1.15 and a debt-to-equity ratio of 1.94. IQVIA Holdings Inc. has a twelve month low of $146.00 and a twelve month high of $254.05. The company has a market cap of $46.58 billion, a price-to-earnings ratio of 37.55, a price-to-earnings-growth ratio of 2.36 and a beta of 1.45.

IQVIA (NYSE:IQV) last posted its earnings results on Thursday, April 22nd. The medical research company reported $2.18 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.85 by $0.33. IQVIA had a net margin of 3.40% and a return on equity of 20.96%. The business had revenue of $3.41 billion for the quarter, compared to analyst estimates of $3.18 billion. During the same quarter in the prior year, the firm earned $1.50 EPS. The firm’s quarterly revenue was up 23.8% compared to the same quarter last year. As a group, sell-side analysts predict that IQVIA Holdings Inc. will post 8.15 EPS for the current fiscal year.

A number of brokerages have recently weighed in on IQV. Truist boosted their price objective on shares of IQVIA from $235.00 to $260.00 in a research note on Monday, April 26th. Citigroup upped their target price on shares of IQVIA from $225.00 to $265.00 in a research note on Friday, April 23rd. Robert W. Baird upped their target price on shares of IQVIA from $238.00 to $250.00 and gave the company an “outperform” rating in a research note on Friday, April 23rd. They noted that the move was a valuation call. Barclays upped their target price on shares of IQVIA from $260.00 to $285.00 and gave the company an “overweight” rating in a research note on Tuesday, July 13th. Finally, Argus upped their target price on shares of IQVIA from $220.00 to $260.00 and gave the company a “buy” rating in a research note on Wednesday, May 12th. Two investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. IQVIA presently has an average rating of “Buy” and an average target price of $248.84.

IQVIA Profile

IQVIA Holdings Inc provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Featured Story: What is a Secondary Public Offering?

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV).

Institutional Ownership by Quarter for IQVIA (NYSE:IQV)

Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.